| CAS NO: | 301356-95-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 457.27 |
|---|---|
| Formula | C15H9BrN2O6S2 |
| CAS No. | 301356-95-6 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: ≥ 90mg/mL |
| Water: N/A | |
| Ethanol: N/A | |
| Chemical Name | 2-((5Z)-5-(5-Bromo-2-oxo-1H-indol-3-ylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)butanedioic acid |
| Synonyms | BCL6 Inhibitor; 79-6; CID5721353; CID-5721353; CID 5721353 |
| SMILES Code | O=C(O)C(N(C/1=O)C(SC1=C2C(NC3=C/2C=C(Br)C=C3)=O)=S)CC(O)=O |
Purity ≥98%
COA
MSDS
CADD selection identifies BCL6 inhibitor compounds. Cancer Cell. 2010 Apr 13;17(4):400-11. |
Crystallography of the BCL6BTB/79-6 complex. Cancer Cell. 2010 Apr 13;17(4):400-11. |
Nuclear magnetic resonance spectroscopy of BCL6BTB with 79-6. Cancer Cell. 2010 Apr 13;17(4):400-11. |
Binding curves for 79-6 to the BCL6BTB.
Compound 79-6 inhibits the growth of primary human DLBCLs. |
79-6 specifically inhibits BCL6 repressor activity. Cancer Cell. 2010 Apr 13;17(4):400-11. |
Compound 79-6 effectively distributes to lymphomas after parenteral administration and suppresses DLBCL growth in vivo. Cancer Cell. 2010 Apr 13;17(4):400-11. |
m.cnreagent.com
